26-May-2015, Spontaneous Serious report. (Report duplicates -  Biogen: 2015BI053666)
A Physician reported the case of a 33-Years-old Male patient who received COPAXONE (GLATIRAMER 
ACETATE, Product is a Teva product). 
The patient took COPAXONE for MULTIPLE SCLEROSIS (GLATIRAMER ACETATE, Injection, Unknown, Form 
strength unknown).
While on the suspect medication(s), the patient experienced SUSPECT PML(Serious ) . 
The physician reported suspect PML (progressive multifocal leukoencephalopathy), medically significant, onset 
unknown.
At the time of the report the outcome of the AEs were:   SUSPECT PML : Unknown.
Action taken with suspect drugs: COPAXONE - Dosage maintained.
The patient had medical history of MULTIPLE SCLEROSIS(Continuing).
The patient's concomitant medication were unspecified.
The patient's past medication were unspecified.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 492 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
Lab tests were not reported.
This case was considered serious based on the following criteria: (Other Serious (Important Medical Events))
Teva Comment:  GLATIRAMER ACETATE. According to the data accumulated so far in the clinical studies, as well
as in the post marketing experience no correlation was found between Copaxone treatment and the development of
malignancies, therefore this event is assessed as not related.
Because this is a spontaneous case, regulatory distribution will be handled as though it is a related case.